Melissa Aldinger

474 total citations
11 papers, 22 citations indexed

About

Melissa Aldinger is a scholar working on Infectious Diseases, Oncology and Molecular Biology. According to data from OpenAlex, Melissa Aldinger has authored 11 papers receiving a total of 22 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Infectious Diseases, 6 papers in Oncology and 3 papers in Molecular Biology. Recurrent topics in Melissa Aldinger's work include SARS-CoV-2 and COVID-19 Research (6 papers), COVID-19 Clinical Research Studies (5 papers) and CRISPR and Genetic Engineering (2 papers). Melissa Aldinger is often cited by papers focused on SARS-CoV-2 and COVID-19 Research (6 papers), COVID-19 Clinical Research Studies (5 papers) and CRISPR and Genetic Engineering (2 papers). Melissa Aldinger collaborates with scholars based in United States, Italy and United Kingdom. Melissa Aldinger's co-authors include Franco Locatelli, Andrew Skingsley, Amanda Peppercorn, Pietro Merli, Elizabeth Alexander, Swati Naik, Adrienne E. Shapiro, Federica Galaverna, Gretja Schnell and Xiaobin Li and has published in prestigious journals such as Blood, Clinical Pharmacology & Therapeutics and Open Forum Infectious Diseases.

In The Last Decade

Melissa Aldinger

9 papers receiving 22 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Melissa Aldinger United States 3 11 8 5 4 4 11 22
Rebecca Gonzalez United States 4 7 0.6× 11 1.4× 5 1.0× 5 1.3× 5 1.3× 9 32
Nedyalko Petrov United Kingdom 4 6 0.5× 4 0.5× 8 1.6× 10 2.5× 3 0.8× 7 29
Mikhail Gilyarov Russia 2 20 1.8× 3 0.4× 7 1.4× 4 1.0× 3 0.8× 2 37
Martin Čerňan Czechia 3 7 0.6× 7 0.9× 2 0.4× 4 1.0× 9 2.3× 7 20
Varun Bafna India 2 26 2.4× 4 0.5× 3 0.6× 3 0.8× 3 0.8× 4 29
Nick Neuwinger Germany 4 11 1.0× 5 0.6× 13 2.6× 7 1.8× 2 0.5× 5 30
Marina Kosinova Russia 3 5 0.5× 15 1.9× 8 1.6× 6 1.5× 4 1.0× 7 28
Yanping Cai China 3 9 0.8× 4 0.5× 3 0.6× 1 0.3× 3 0.8× 4 23
Marisa Di Natale Spain 3 13 1.2× 2 0.3× 4 0.8× 4 1.0× 2 0.5× 5 29
Jörg Martens Germany 4 3 0.3× 6 0.8× 5 1.0× 3 0.8× 10 2.5× 6 27

Countries citing papers authored by Melissa Aldinger

Since Specialization
Citations

This map shows the geographic impact of Melissa Aldinger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Melissa Aldinger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Melissa Aldinger more than expected).

Fields of papers citing papers by Melissa Aldinger

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Melissa Aldinger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Melissa Aldinger. The network helps show where Melissa Aldinger may publish in the future.

Co-authorship network of co-authors of Melissa Aldinger

This figure shows the co-authorship network connecting the top 25 collaborators of Melissa Aldinger. A scholar is included among the top collaborators of Melissa Aldinger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Melissa Aldinger. Melissa Aldinger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
Agostini, Maria L., Gretja Schnell, Julia di Iulio, et al.. (2024). Resistance analysis in the phase III COMET-TAIL study: treatment of COVID-19 with intramuscular or intravenous sotrovimab. Future Virology. 19(5). 185–198.
2.
Sager, Jennifer E., Sergio Parra, Jennifer Moore, et al.. (2024). Pharmacokinetics of the Monoclonal Antibody, Sotrovimab, in Healthy Participants Following IM Administration at Different Injection Sites. Clinical Pharmacology & Therapeutics. 117(3). 759–767.
3.
Schnell, Gretja, Julia di Iulio, Anil Kumar Gupta, et al.. (2023). Resistance Analysis Following Sotrovimab Treatment in Participants with COVID-19 During the Phase III COMET-ICE Study. Future Virology. 18(15). 975–990. 2 indexed citations
4.
Sager, Jennifer E., Julie Passarell, Xiaobin Li, et al.. (2023). Population pharmacokinetics and exposure‐response analysis of a single dose of sotrovimab in the early treatment of patients with mild to moderate COVID‐19. CPT Pharmacometrics & Systems Pharmacology. 12(6). 853–864. 5 indexed citations
5.
Reyes, Carolina, Melissa Aldinger, Elizabeth Alexander, et al.. (2023). Assessment of symptoms in COMET-ICE, a phase 2/3 study of sotrovimab for early treatment of non-hospitalized patients with COVID-19. Journal of Patient-Reported Outcomes. 7(1). 92–92. 1 indexed citations
6.
Moya, Jaynier, Sergio Parra, Erick Stanley Petersen Juárez, et al.. (2023). Safety, Virology, Pharmacokinetics, and Clinical Experience of High-Dose Intravenous Sotrovimab for the Treatment of Mild to Moderate COVID-19: An Open-Label Clinical Trial. Open Forum Infectious Diseases. 10(7). ofad344–ofad344. 2 indexed citations
7.
Agostini, Maria L., Gretja Schnell, Julia di Iulio, et al.. (2022). 1150. Resistance Analysis in the COMET-TAIL Study: Participants with Mild-to-Moderate COVID-19 Treated with Intramuscular or Intravenous Sotrovimab. Open Forum Infectious Diseases. 9(Supplement_2). 3 indexed citations
8.
9.
Naik, Swati, Susanne H.C. Baumeister, Victor Aquino, et al.. (2018). Administration of BPX-501 Cells Following Αβ- T and B-Cell-Depleted HLA-Haploidentical HSCT in Children with Fanconi Anemia. Blood. 132(Supplement 1). 4654–4654. 1 indexed citations
10.
11.
Jacobsohn, David A., Rajni Agarwal, Swati Naik, et al.. (2018). Administration of Rimiducid Following Haploidentical BPX-501 Cells in Children with Malignant or Non-Malignant Disorders Who Develop Graft-Versus-Host-Disease (GvHD). Blood. 132(Supplement 1). 2207–2207. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Rebecca Gonzalez Breakdown of academic impact, for papers by Nedyalko Petrov Breakdown of academic impact, for papers by Mikhail Gilyarov Breakdown of academic impact, for papers by Martin Čerňan Breakdown of academic impact, for papers by Varun Bafna Breakdown of academic impact, for papers by Nick Neuwinger Breakdown of academic impact, for papers by Marina Kosinova Breakdown of academic impact, for papers by Yanping Cai Breakdown of academic impact, for papers by Marisa Di Natale Breakdown of academic impact, for papers by Jörg Martens
Rankless by CCL
2026